Cover Image
市場調查報告書

化療誘發性噁心和嘔吐(CINV) - 開發中產品分析

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245963
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
化療誘發性噁心和嘔吐(CINV) - 開發中產品分析 Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 93 Pages
簡介

化療誘發性噁心和嘔吐(CINV)是化療所引起的心律上升、發汗、暈眩、唾液增加等噁心嘔吐的症狀,發病要素一般認為是年齡、藥物、給藥、給藥行程及給藥途徑等。

本報告提供化療誘發性噁心和嘔吐(CINV)之治療藥開發情形調查分析,提供您開發中產品概要、臨床實驗的各階段產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

化療誘發性噁心和嘔吐(CINV)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

治療藥的開發企業

  • Kyowa Hakko Kirin
  • BioDelivery Sciences International, Inc.
  • Heron Therapeutics, Inc.
  • Suda Ltd
  • Aphios Corporation
  • Genovate Biotechnology Co., LTD.
  • Teikoku Pharma USA, Inc.
  • SymBio Pharmaceuticals Limited
  • INSYS Therapeutics, Inc.
  • Helsinn Healthcare S.A.
  • 新日本化學
  • Acacia Pharma Ltd.
  • Helsinn Holding S.A.
  • RedHill Biopharma Ltd.
  • Tesaro, Inc.

治療藥的評估

  • 單獨療法的產品
  • 聯合治療的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • granisetron - Drug Profile
  • palonosetron hydrochloride - Drug Profile
  • (netupitant + palonosetron) - Drug Profile
  • rolapitant hydrochloride - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • ondansetron hydrochloride CR - Drug Profile
  • (netupitant + palonosetron) - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • dronabinol - Drug Profile
  • rolapitant hydrochloride - Drug Profile
  • granisetron - Drug Profile
  • (netupitant + palonosetron) - Drug Profile
  • APD-403 - Drug Profile
  • granisetron - Drug Profile
  • APD-421 - Drug Profile
  • ondansetron hydrochloride - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • dronabinol - Drug Profile
  • TPW-146 - Drug Profile
  • ondansetron hydrochloride - Drug Profile
  • granisetron - Drug Profile

開發中產品的最新趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 關註資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8296IDB

Summary

Global Markets Direct's, 'Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2016', provides an overview of the Chemotherapy Induced Nausea and Vomiting pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting
  • The report reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chemotherapy Induced Nausea and Vomiting therapeutics and enlists all their major and minor projects
  • The report assesses Chemotherapy Induced Nausea and Vomiting therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chemotherapy Induced Nausea and Vomiting Overview
    • Therapeutics Development
  • Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Overview
  • Chemotherapy Induced Nausea and Vomiting - Therapeutics under Development by Companies
  • Chemotherapy Induced Nausea and Vomiting - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Chemotherapy Induced Nausea and Vomiting - Products under Development by Companies
  • Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development
    • Acacia Pharma Limited
    • Aphios Corporation
    • Astellas Pharma Inc.
    • Athenex, Inc.
    • Helsinn Healthcare S.A.
    • Heron Therapeutics, Inc.
    • INSYS Therapeutics, Inc.
    • Kyowa Hakko Kirin Co., Ltd.
    • Nemus Bioscience, Inc.
    • RedHill Biopharma Ltd.
    • SoluBest Ltd.
    • Suda Ltd
    • Tesaro, Inc.
    • Therapix Biosciences Ltd
  • Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (netupitant + palonosetron hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (palonosetron hydrochloride + Pro-netupitant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APD-403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aprepitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aprepitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FK-886 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • granisetron - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • granisetron ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • granisetron ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • granisetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LPI-1504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LPI-1505 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-1222 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • netupitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palmidrol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rolapitant hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chemotherapy Induced Nausea and Vomiting - Dormant Projects
  • Chemotherapy Induced Nausea and Vomiting - Discontinued Products
  • Chemotherapy Induced Nausea and Vomiting - Product Development Milestones
    • Featured News & Press Releases
      • Jun 23, 2016: TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer
      • Jun 04, 2016: TESARO Provides Update on Rolapitant IV at ASCO Investor Briefing
      • May 18, 2016: TESARO Announces Two Abstracts on (VARUBI) Rolapitant to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting
      • Apr 18, 2016: Heron Therapeutics Provides Update on FDA Review of SUSTOL NDA
      • Mar 23, 2016: TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency
      • Mar 14, 2016: TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration
      • Mar 03, 2016: Heron Therapeutics Provides Update on SUSTOL (granisetron) Injection NDA
      • Feb 29, 2016: Heron Therapeutics Provides Update on SUSTOL NDA
      • Feb 01, 2016: Biologics Announces New Oncology Partnership
      • Jan 15, 2016: Heron Therapeutics Notified by FDA That It Will Not Take Action on SUSTOL New Drug Application by the PDUFA Date
      • Dec 15, 2015: Swissmedic Approves Akynzeo (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting in Switzerland
      • Nov 16, 2015: OPKO Licensee TESARO Announces the Launch of VARUBI (Rolapitant) in the United States
      • Nov 13, 2015: Helsinn Group and Eisai Announce Inclusion of AKYNZEO in American Society of Clinical Oncology Antiemetics Guid
      • Oct 14, 2015: Helsinn's AKYNZEO (netupitant/palonosetron) nominated within the category "Best Pharmaceutical Agent of the Year" at The Galien Foundation Prix Award
      • Oct 14, 2015: Luxena Received FDA Orphan Drug Designation for LPI-1503
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Limited, H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corporation, H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc., H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Athenex, Inc., H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Helsinn Healthcare S.A., H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics, Inc., H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Nemus Bioscience, Inc., H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd., H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro, Inc., H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Therapix Biosciences Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Dormant Projects (Contd..1), H2 2016
  • Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top